Participated · Series A · Jul 2026

Brenus Pharma is advancing an off-the-shelf platform in immuno-oncology that mimics tumor protein expression to make tumors visible to the immune system. Its lead clinical-stage asset is STC-1010 (NCT06934538), targeting MSS metastatic colorectal cancer, and recent execution across clinical, regulatory and business development milestones has been highlighted by the company. Brenus positions its technology for multi-asset expansion and plans to use new capital to complete the Phase I program for STC-1010 and to advance its next drug candidate. The company has raised a total of €38 million since inception following the €11 million Series A extension. The firm announced the financing from Lyon, France and continues engaging both existing and new international investors to support its development plans.

Participated · Series B · Mar 2026

Standing Ovation develops a patented precision fermentation process that upcycles whey permeates and agricultural sugars into high-quality casein proteins used across the agrifood industry. The company has protected its technology with eight patent families and positions its approach as a circular alternative to traditional animal casein. An ISO-certified life cycle assessment cited by the company indicates a 74% reduction in greenhouse gas emissions and up to three times less water use versus animal casein. By repurposing dairy side-streams that were previously low-value, Standing Ovation aims to create new revenue streams for producers and reduce reliance on international supply chains. The company has attracted institutional and strategic investors including Astanor, Bel Group, Seventure Partners, Big Idea Ventures and Danone Ventures. With the recent Series B and accompanying non-dilutive financing, Standing Ovation is funding commercial rollout in the U.S. and planned expansion into Europe and Asia starting at the end of 2027.

Participated · Series A · Dec 2025

Based in Clermont-Ferrand with offices in Lyon, Axoltis Pharma researches and develops innovative treatments for neurodegenerative and neurotraumatic diseases. Its lead asset, NX210c, is a 12-amino-acid cyclic peptide derived from SCO-Spondin that promotes blood–brain barrier restoration, offers neuroprotection, and enhances neurotransmission. The candidate holds orphan-drug designations from both the FDA and the EMA and demonstrated a favorable safety profile in a 2023 Phase 1b study. NX210c is now being evaluated in the Phase 2 SEALS trial in 82 ALS patients across 16 investigational centers, with results expected in Q2 2026. Proceeds from the latest capital raise will fund completion of this study and support exploratory work in additional neurological indications. The compound is protected by seven patents owned by Axoltis, and the company is actively pursuing a global pharmaceutical partnership, targeting discussions at the 2026 JP Morgan Healthcare Conference. While the company has not yet disclosed revenue, its financing underscores investor confidence in the differentiated technology and market potential.

Led · Equity · Feb 2024

Pixee Medical develops augmented- and mixed-reality navigation platforms for orthopedic implant placement, including Knee+ for total knee replacement and Shoulder+ for total shoulder replacement. Its Knee+ system combines augmented-reality glasses and reusable instruments, has CE certification and FDA 510(k) clearance, and has been used in more than 5,000 patient procedures worldwide. Shoulder+ obtained CE mark certification in 2023 and is anticipating FDA approval by the end of the year. The company says clinical studies have validated the precision and effectiveness of its technology and positions its solutions for ambulatory surgery centers. Pixee plans to accelerate U.S. expansion with a subsidiary opening in the first quarter, deploy a new range of augmented reality navigation platforms, open an office in Singapore to expand in Asia, and hire additional talent. The company was founded in 2018 and is advancing next-generation products that incorporate immersive technologies, connectivity, and artificial intelligence. The recent capital raise will support these product and geographic expansion plans.

Participated · Equity · Mar 2020

Founded in 2016 in Lyon, Club Employés offers a dual model: a software suite that lets works councils (CSEs) administer subsidies, e-vouchers, gift cards, culture- and sport-related perks, and a marketplace aggregating hundreds of thousands of discounted deals. The company serves more than 10,000 corporate clients and 1.6 million end-users, positioning itself among the top three French players alongside Swile and Edenred. Club Employés generated €60 million in revenue last year and became profitable in 2024; it targets €100 million in revenue by 2025 and €300 million “in the short term.” The scale-up employs 350 people today and plans to reach 500 within 12–18 months. Recent product road-map items include a new payment card and deeper platform personalization. International expansion is under way, with a first office in the United Kingdom already open and launches in Belgium, Italy, and eventually the United States on the horizon. The company’s mission is to boost purchasing power by making employee perks truly accessible.